ArticleMolecular biology reports2026
Remodeling-phase wound-derived protein factors enhance mesenchymal stem cell function and improve diabetic wound healing.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChronic diabetic wounds result from dysregulated inflammatory responses and impaired progression from the inflammatory to proliferative and remodeling phases of healing. Although mesenchymal stem cells (MSCs) possess regenerative and paracrine potential, their function is compromised within the diabetic wound microenvironment. This study aimed to enhance wound healing by transplanting MSCs conditioned with remodeling-phase wound-derived factors.
methodsIn this preclinical study, bone marrow-derived MSCs were isolated and characterized. Wound extracts from normal and streptozotocin-induced diabetic rats were evaluated, and the non-cytotoxic concentration (10 µg/mL) was used for conditioning. Functional assessment included in vitro scratch assays, gene expression analysis of inflammatory and regenerative mediators, and transplantation in a diabetic wound model, histological (H&E) and immunofluorescence (α-SMA) analyses.
resultsNormal Day 9 wound extract (N9)-conditioned MSCs demonstrated enhanced wound closure in vitro. In contrast, Diabetic Day 9 wound extract (D9)-conditioned MSCs exhibited elevated expression of inflammatory genes and reduced expression of angiogenic and proliferative markers. In vivo, N9-conditioned MSCs significantly accelerated wound closure, restored tissue architecture, improved collagen organization, and increased the number of α-SMA-positive vascular structures, supporting enhanced vascular remodeling.
conclusionConditioning MSCs with remodeling-phase-derived factors present in normal Day 9 wound extract (N9) increases their therapeutic efficacy in diabetic wound healing. This preclinical strategy supports the use of phase-specific wound cues to optimize stem cell-based therapy and facilitate transition toward tissue regeneration.
Indexed as
Identifiers
42690285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.